Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1Dermatologic 1

Conditions

Melanoma 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Subcutaneous panniculitis-like T-cell lymphoma 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

fludarabine phosphate 23Peripheral Blood Stem Cell Transplantation 23Cyclophosphamide 20Whole-Body Irradiation 18Mycophenolic Acid 16Cyclosporine 15Etoposide 11Tacrolimus 10Busulfan 10Antilymphocyte Serum 10Methotrexate 9Melphalan 9Bortezomib 9Vorinostat 6Rituximab 6Filgrastim 6Doxorubicin 6Vincristine 5Therapeutics 5Prednisone 5Lenalidomide 5tanespimycin 4Sirolimus 4Radiotherapy 4Psychiatric Rehabilitation 4Methylprednisolone 4Everolimus 4Carboplatin 4pembrolizumab 3Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × prednylidene × Dermatologic × Clear all
NCT01746992 2017-11-14

CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma

Ruijin Hospital

Phase 4 Unknown
200 enrolled
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡